HIPP RAYMOND R 4
4 · NEOGENOMICS INC · Filed Feb 28, 2019
Insider Transaction Report
Form 4
HIPP RAYMOND R
Director
Transactions
- Sale
Common Stock
2019-02-26$18.90/sh−18,889$357,002→ 287,580 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-02-26−5,556→ 2,777 totalExercise: $9.11From: 2017-07-28Exp: 2021-07-28→ Common Stock (5,556 underlying) - Exercise/Conversion
Common Stock
2019-02-26$4.78/sh+10,000$47,800→ 297,580 total - Exercise/Conversion
Common Stock
2019-02-26$7.27/sh+3,333$24,231→ 306,469 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-02-26−10,000→ 0 totalExercise: $4.78From: 2016-05-06Exp: 2020-05-06→ Common Stock (10,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2019-02-26−3,333→ 6,667 totalExercise: $7.27From: 2018-05-25Exp: 2022-05-25→ Common Stock (3,333 underlying) - Exercise/Conversion
Common Stock
2019-02-26$9.11/sh+5,556$50,615→ 303,136 total
Holdings
- 3,017
Stock Option (Right to Buy)
Exercise: $11.60From: 2019-06-01Exp: 2023-06-01→ Common Stock (3,017 underlying)
Footnotes (3)
- [F1]On May 6, 2015, Mr. Hipp was granted 10,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F2]On July 28, 2016, Mr. Hipp was granted 8,333 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F3]On May 25, 2017, Mr. Hipp was granted 10,000 stock options. The options vest ratably on the next three anniversary dates of the grant date.